Owen Mumford this week announced that it has started building its new production facility in Witney, Oxfordshire in the U.K.

Owen Mumford’s new Witney facility will stand as a production site for the company’s recently launched, next-generation auto-injector Aidaptus. The company has decades of experience creating its own drug delivery, blood sampling and rapid diagnostic products — as well as creating devices for major pharmaceutical and diagnostics companies.

The new building is commissioned to align with the Woodstock, England–based company’s sustainability agenda that is in accordance with the latest environmental standards needed for a BREEAM certification.

The investment project, which is valued at £14 million ($18.6 million), will facilitate Owen Mumford’s development of medical devices through sustainable design and manufacturing methods. The BREEAM certification will recognize the highest levels of environmental, social and economic sustainability performance. The company has worked closely with ecologist specialists to ensure there is no negative impact on biodiversity.

“Since we first started to significantly ramp up our sustainability agenda in 2014, we have achieved many important milestones, and today’s groundbreaking ceremony at our new Witney site is a fitting tribute to the journey we are on,” CEO Jarl Severn said in a November 29 news release. “We are setting the benchmark high for manufacturing to do its part in the overall reduction of environmental impact. Our investment in this new facility supports the promises we make to all our stakeholders by providing the very best platform for innovation in our products, but most importantly by doing it in a truly responsible and ethical way.”